Advertisement
Mayo Clinic Proceedings Home

In reply—The “Perfect Cytokine Storm” of COVID-19

      We read with great interest the letter by Testori regarding our review article.
      • Vijayvargiya P.
      • Garrigos Z.E.
      • Castillo Almeida N.E.
      • Gurram P.R.
      • Stevens R.W.
      • Razonable R.R.
      Treatment considerations for COVID-19: a critical review of the evidence (or lack thereof).
      Testori pointed out the important association of proinflammatory cytokines in the pathogenesis of coronavirus disease 2019 (COVID-19), which could account for the worse outcome in older individuals. Strategies to combat the proinflammatory state, using multiple investigational compounds, are in the pipeline as potential treatment modalities for COVID-19.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vijayvargiya P.
        • Garrigos Z.E.
        • Castillo Almeida N.E.
        • Gurram P.R.
        • Stevens R.W.
        • Razonable R.R.
        Treatment considerations for COVID-19: a critical review of the evidence (or lack thereof).
        Mayo Clin Proc. 2020; 95: 2037-2038
      1. Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia. APHP website.
        • Richardson P.
        • Griffin I.
        • Tucker C.
        • et al.
        Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
        Lancet. 2020; 395: e30-e31
        • Stebbing J.
        • Phelan A.
        • Griffin I.
        • et al.
        COVID-19: combining antiviral and anti-inflammatory treatments.
        Lancet Infect Dis. 2020; 20: 400-402
      2. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. National Institute of Allergy and Infectious Diseases website.
        • Wang Y.
        • Zhang D.
        • Du G.
        • et al.
        Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
        Lancet. 2020; 395: P1569-P1578